Curtis – who first joined the firm in 2010 as VP of product development –will now be responsible for chemistry, manufacturing and controls functions, toxicology, and regulatory approvals.
He will also continue in his duties leading the company’s product development strategy.
Michael Jioursek, chief scientific officer and co-founder of Catabasissaid orf Curtis: “Under his guidance, Catabasis recently and successfully initiated a Phase 1 clinical trial of CAT-1004, our lead compound in type 2 diabetes. Michael is a critical member of the Catabasis team, and we are pleased to promote him to this new role.”
Michael Hufford, chief operating officer at NeuroCog Trials Andrea Schiefer, VP of European clinical operations at Clinipace John Larus, executive VP of clinical operations at Clinipace David Avakian, PHT Corporation's new chief architect Matt Collins, VP, director of interactive technology at AbelsonTaylor Mike Curtis, senior VP of product development and regulatory affairs at Catabasis.